Drug Profile
Endothelial stem cell therapy - CellProThera
Latest Information Update: 06 Feb 2023
Price :
$50
*
At a glance
- Originator CellProthera
- Class Cardiovascular therapies; Haematopoietic stem cells therapies
- Mechanism of Action Angiogenesis inducing agents; Cell replacements; Endothelial cell modulators; Haematopoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Myocardial infarction
Most Recent Events
- 01 Feb 2023 CellProthera and BioCardia enhance the agreement to complete the ongoing phase I/IIb EXCELLENT trial for the treatment of Acute myocardial infarction in Europe and potential early access for patients
- 05 Mar 2021 Endothelial stem cell therapy is still in phase I/II trials for Myocardial infarction in France and United Kingdom (Intracardiac)
- 30 Dec 2020 BioCardia has patent protection for technology that enhances control for cardiac therapies in USA